Tirzepatide for Weight Loss: The Next-Generation GLP-1 Treatment
🔥Why Tirzepatide Is Generating Buzz in Weight Loss & GLP-1 Treatments
If you thought semaglutide was impressive, meet tirzepatide — marketed under brand names like Mounjaro® (for diabetes) and Zepbound™ (for weight loss).
This medication has been making headlines because clinical studies show it may help people lose even more weight than semaglutide, often with noticeable results in just weeks.
🍂 Seasonal Tip: Start your tirzepatide program in fall, and you could be enjoying a slimmer, more energized you before the holiday season begins. Whether you live in Payson, Spanish Fork, Springville, or Provo — or join us via nationwide telehealth — we can help you get started.
💉What Is Tirzepatide? (Dual GLP-1/GIP Weight Loss Injection)
Tirzepatide is a dual-acting GLP-1/GIP receptor agonist — meaning it works on two key hormone pathways that control hunger and blood sugar.
- Brand names: Mounjaro® (type 2 diabetes), Zepbound™ (weight loss)
- Administration: Once-weekly injection, self-administered
- FDA approval for weight loss: November 2023
This next-generation approach to GLP-1 therapy may offer faster and more significant weight loss for some patients compared to earlier medications.
🧠How Tirzepatide Works in the Body for Rapid Weight Loss
Tirzepatide targets two hormones:
- GLP-1 (Glucagon-like peptide-1): Slows digestion, stabilizes blood sugar, and reduces appetite.
- GIP (Glucose-dependent insulinotropic polypeptide): Enhances the body’s insulin response and may improve fat metabolism.
💡 Why it matters: By activating both GLP-1 and GIP receptors, tirzepatide may provide more powerful appetite suppression and greater metabolic benefits than GLP-1 medications alone.
📊Tirzepatide Weight Loss Results from Clinical Studies
In the SURMOUNT-1 clinical trial:
- 5 mg: ~15% average body weight lost (72 weeks)
- 10 mg: ~20% average body weight lost (72 weeks)
- 15 mg: ~22.5% average body weight lost (72 weeks)
⏱ Timeline for results: Many patients notice appetite changes within the first 1–2 weeks, with visible weight loss often by the end of the first month.
⚠️Potential Side Effects & Safety Considerations for Tirzepatide
Common side effects:
- Nausea
- Constipation or diarrhea
- Mild fatigue
- Occasional headaches
Who should avoid tirzepatide:
- Individuals with a personal/family history of medullary thyroid carcinoma or MEN2
- Those with active pancreatitis
💡 Tip: At Wasatch Advanced Wellness, we start with the lowest effective dose and gradually increase, helping minimize side effects and maximize results.
⚖️Tirzepatide vs Semaglutide: Which GLP-1 Medication Works Faster?
Tirzepatide
- Hormone Targets: GLP-1 + GIP
- Average Weight Loss: 20–22%
- Speed of Results: Often faster
- Years on Market: Newer (2023 approval)
Semaglutide
- Hormone Targets: GLP-1 only
- Average Weight Loss: 15–20%
- Speed of Results: Slightly slower
- Years on Market: Longer track record
💡 Bottom line: Tirzepatide may be the better choice if you’re looking for maximum weight loss in the shortest time — but semaglutide remains an excellent, well-researched option.
💵Cost, Payment Options & Pharmacy Process for Tirzepatide Programs
At Wasatch Advanced Wellness:
- We do not accept insurance for weight loss medications.
- We do accept HSA (Health Savings Account) cards.
- Prescriptions are sent to a trusted compounding pharmacy, which ships your medication directly to you.
- Compounded tirzepatide is often significantly more affordable than brand-name versions.
🩺How to Start Tirzepatide Weight Loss Treatment in Utah County or via Telehealth
- Book Your Virtual or In-Office Consultation – Serving Payson, Spanish Fork, Springville, Provo, and nationwide telehealth.
- Personalized Plan – Based on your health, goals, and preferences.
- Prescription Sent to Compounding Pharmacy – Direct shipping to your home.
- Ongoing Support – Regular follow-ups to ensure safe, steady progress.
📅 Special Fall Booking: Start now to see results before the holidays!
👉 Book Your Consultation Now
❓ FAQS
- Is tirzepatide better for weight loss than semaglutide?
For many patients, tirzepatide may lead to faster results and slightly higher average weight loss percentages. However, semaglutide has a longer safety track record. The best choice depends on your health profile, weight loss goals, and how quickly you want to see results. - How quickly will I see weight loss results with tirzepatide?
Many people notice appetite suppression within 1–2 weeks, with visible weight loss often appearing by the end of the first month — sometimes sooner than with semaglutide. - Is tirzepatide safe for adults over 40 or those with slow metabolism?
Yes, tirzepatide can be very effective for adults over 40 who struggle with stubborn weight. The dual-hormone action may help address hormonal and metabolic changes that make weight loss harder with age. - Can I get tirzepatide through telehealth if I’m not in Utah?
Yes — we offer nationwide telehealth consultations. You’ll receive the same personalized plan and support as our in-clinic patients in Utah County. - How much does tirzepatide cost compared to semaglutide?
Compounded tirzepatide is often more affordable than brand-name versions and may be priced similarly to compounded semaglutide. We also accept HSA cards for payment. - What are the most common tirzepatide side effects?
Mild nausea, digestive changes, fatigue, and headaches are the most common. These often fade as your body adjusts. We start with the lowest effective dose to minimize discomfort.
🔬 References
- American Diabetes Association. (n.d.). GLP-1 receptor agonists. Diabetes.org. Retrieved August 11, 2025, from https://diabetes.org/tools-support/medication/medications-type-2/GLP-1-receptor-agonists
- Food and Drug Administration. (2023). Zepbound (tirzepatide) prescribing information. U.S. Food and Drug Administration. Retrieved August 11, 2025, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215866s000lbl.pdf
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & Kushner, R. F. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038